Biotech | January 18, 2022
DCGI approves Phase 3 clinical trial of Stempeucel to treat Covid-19 patients
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
The study will be published on the pre-print server, medRXiv, shortly
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
Subscribe To Our Newsletter & Stay Updated
